Editas Medicine, Inc. (NASDAQ:EDIT) share price swings at $22.30 with percentage change of -10.48% in most recent trading session.
Lets us look over what analysts have to say about performance of the EDIT. EPS is usually the indicator of profitability for the company. According to WSJ analysis, the Q4 2016 current estimates trends were for $-0.69 as compared to the next year Q1 current trend of $-0.69. While on annual basis the current EPS estimates trend for FY 2017 came in for $-2.86 as compared to three months ago $-3.01.
The stock prices target chart showed high target of 40 kept by analysts at WSJ while the average price target was for 33.50 as compared to current price of 22.30. Somehow, the stock managed to gain BUY ratings by 3 analysts in current tenure as 2 analysts having overweight ratings, 2 recommend as HOLD. Overall, the consensus ratings were for Overweight by the pool of analysts. Moving toward returns ratio, EDIT has returns on investment of -54.10% which indicates firm’s investment efficiency or to compare the efficiency of a number of different investments.
While returns on assets calculated as -40.10% that gives an idea about how efficient management is at using its assets to generate earnings. Editas Medicine, Inc. (NASDAQ:EDIT) has returns on equity of -56.10%, which is measuring a corporation’s profitability by revealing how much profit generates by EDIT with the shareholders’ money. The firm attains analyst recommendation of 2.20 on scale of 1-5 with week’s performance of -11.01%.
Effective Investment Valuation
Furthermore, it has price to sale ratio of 126.82 that signifies the value placed on each dollar of a firm’s sales or incomes. The firm’s price to book was 5.93, which can be compared with current price to get idea about under or overvalue of stock.
To have technical views, liquidity ratio of Editas Medicine, Inc. (NASDAQ:EDIT) calculated as 5.70 to match up with its debt to equity ratio of 0.34. The float short ration was 10.64%; as compared to Short Ratio were 4.86. The firm has institutional ownership of 75.10%, while insider ownership included 0.30%.